Ligand Pharmaceuticals Financial Ratios
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ligand Pharmaceuticals ratio analysis
Ligand Pharmaceuticals earned a net margin of 46.4% in FY 2025, up from -2.4% a year earlier. Return on equity reached 12.2%, meaning Ligand Pharmaceuticals generated 0.12 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.44 versus 0.00 the year before, and the current ratio was 22.23.
At the end of FY 2025, LGND traded at 31.0 times earnings; across the 6 fiscal years shown, its year-end P/E ranged from 2.0 to 161.2, with a median of 26.7. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Ligand Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 31.01 | — | 24.29 | — | 29.11 | — | 1.98 | 14.42 | 161.17 | — |
| Price / sales | 13.71 | 12.10 | 9.41 | 5.74 | 6.63 | 6.14 | 9.97 | 7.23 | 12.73 | 12.12 |
| Price / book | 3.61 | 2.44 | 1.76 | 1.89 | 1.95 | 1.42 | 1.56 | 3.24 | 4.49 | 3.87 |
| Gross margin | — | — | — | — | — | — | — | 97.5% | 96.2% | 94.9% |
| Operating margin | 15.3% | -13.5% | 9.1% | 1.5% | 43.0% | 22.9% | 671.0% | 65.1% | 48.2% | 40.3% |
| Net margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | -1.8% | 523.2% | 57.0% | 8.9% | -1.5% |
| Free cash flow margin | 18.2% | 57.0% | 35.1% | 61.1% | 29.0% | 30.6% | -26.5% | 76.8% | 61.2% | 54.0% |
| Return on equity (ROE) | 12.2% | -0.5% | 7.4% | -5.6% | 7.0% | -0.4% | 82.0% | 25.6% | 3.1% | -0.5% |
| Return on assets (ROA) | 8.0% | -0.4% | 6.6% | -4.4% | 4.4% | -0.2% | 42.1% | 11.4% | 1.9% | -0.3% |
| Debt / equity | 0.44 | 0.00 | — | — | — | — | — | — | — | — |
| Current ratio | 22.23 | 8.93 | 14.15 | 2.67 | 11.15 | 5.00 | 66.09 | 10.58 | 0.99 | 0.72 |
| Revenue growth | 60.4% | 27.3% | -33.1% | -18.8% | 47.7% | 36.0% | -52.2% | 78.2% | 29.5% | 51.5% |
| EPS growth | — | -107.5% | — | -159.8% | — | -100.6% | 434.4% | 1,024.5% | — | -100.7% |